vs
Side-by-side financial comparison of ASP Isotopes Inc. (ASPI) and Cellectis S.A. (CLLS). Click either name above to swap in a different company.
ASP Isotopes Inc. is the larger business by last-quarter revenue ($16.7M vs $9.5M, roughly 1.8× Cellectis S.A.). On growth, ASP Isotopes Inc. posted the faster year-over-year revenue change (1295.7% vs 375.0%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-47.4M).
ASP Isotopes Inc.ASPIEarnings & Financial Report
ASP Isotopes Inc. is a specialty materials firm focused on developing and producing high-purity custom isotopes. Its products serve key sectors including nuclear medicine, targeted cancer therapies, advanced energy, and industrial research, with customers across North America, Europe and Asia Pacific.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
ASPI vs CLLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $16.7M | $9.5M |
| Net Profit | — | $-25.3M |
| Gross Margin | 12.5% | — |
| Operating Margin | — | -181.1% |
| Net Margin | — | -265.9% |
| Revenue YoY | 1295.7% | 375.0% |
| Net Profit YoY | -586.8% | -51.9% |
| EPS (diluted) | — | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q2 24 | — | $9.5M | ||
| Q3 23 | — | $1.6M | ||
| Q2 23 | — | $2.0M | ||
| Q2 22 | — | $2.7M |
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q2 24 | — | $-25.3M | ||
| Q3 23 | — | $-17.5M | ||
| Q2 23 | — | $-16.6M | ||
| Q2 22 | — | $-19.5M |
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 97.3% | ||
| Q2 22 | — | 87.9% |
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q2 24 | — | -181.1% | ||
| Q3 23 | — | -1258.1% | ||
| Q2 23 | — | -1180.5% | ||
| Q2 22 | — | -1003.0% |
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q2 24 | — | -265.9% | ||
| Q3 23 | — | -1064.1% | ||
| Q2 23 | — | -831.6% | ||
| Q2 22 | — | -714.4% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q2 24 | — | $-0.28 | ||
| Q3 23 | — | $-0.31 | ||
| Q2 23 | — | $-0.20 | ||
| Q2 22 | — | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $333.3M | $149.0M |
| Total DebtLower is stronger | $14.4M | — |
| Stockholders' EquityBook value | $204.2M | $148.6M |
| Total Assets | $498.0M | $407.1M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q2 24 | — | $149.0M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $84.4M | ||
| Q2 22 | — | $129.4M |
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q2 24 | — | $148.6M | ||
| Q3 23 | — | $76.1M | ||
| Q2 23 | — | $96.6M | ||
| Q2 22 | — | $180.5M |
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q2 24 | — | $407.1M | ||
| Q3 23 | — | $209.7M | ||
| Q2 23 | — | $227.7M | ||
| Q2 22 | — | $320.9M |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.8M | $28.9M |
| Free Cash FlowOCF − Capex | $-47.4M | $27.6M |
| FCF MarginFCF / Revenue | -284.7% | 290.5% |
| Capex IntensityCapex / Revenue | 57.9% | 13.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 24 | — | $28.9M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.4M | ||
| Q2 22 | — | $-60.2M |
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 24 | — | $27.6M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.9M | ||
| Q2 22 | — | $-61.7M |
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 24 | — | 290.5% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -2391.4% | ||
| Q2 22 | — | -2266.7% |
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 24 | — | 13.2% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 24.1% | ||
| Q2 22 | — | 56.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
